Sai Life Sciences sets up Peptide Research Center in Hyderabad

Sai Life Sciences, a Contract Research, Development, and Manufacturing Organisation (CRDMO), set up a dedicated Peptide Research Center at its integrated R&D Campus here.

“As the pharmaceutical industry evolves from small molecules to emerging modalities like peptides, we are expanding our capabilities to stay ahead. Our new Peptide Research Center reflects this commitment—designed to meet the growing demand for complex peptide synthesis and conjugation. With this investment, we reinforce our role as a trusted partner in advancing next-generation therapeutics,’‘ Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences said in a release on Thursday. 

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialised services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics.

According to Maneesh Pingle, Head of Discovery Services, Sai Life Sciences, the demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. 

“At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients’ evolving needs as they advance peptide therapies across diverse therapeutic areas,’‘ he said. 

The new Peptide Research Center will be integrated with Sai Life Sciences’ end-to-end discovery services, spanning synthetic and medicinal chemistry, biology and toxicology, among others, the release said.

Published on April 3, 2025